Discounted Cash Flow (DCF) Analysis Levered
Cara Therapeutics, Inc. (CARA)
$11.71
-0.16 (-1.35%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.91 | 13.47 | 19.89 | 135.08 | 23.03 | 133.70 | 776.30 | 4,507.33 | 26,170.21 | 151,947.97 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -54.83 | -22.30 | -109.22 | -5.49 | -60.09 | -1,871.36 | -10,865.38 | -63,085.97 | -366,286.19 | -2,126,710.05 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.06 | -0.07 | -0.02 | -0.35 | -0.04 | -1.99 | -11.53 | -66.95 | -388.72 | -2,256.99 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -54.89 | -22.37 | -109.24 | -5.84 | -60.13 | -1,873.35 | -10,876.91 | -63,152.92 | -366,674.92 | -2,128,967.04 |
Weighted Average Cost Of Capital
| Share price | $ 11.71 |
|---|---|
| Beta | 0.953 |
| Diluted Shares Outstanding | 50.72 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | -% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 8.159 |
| Total Debt | 3.67 |
| Total Equity | 593.92 |
| Total Capital | 597.59 |
| Debt Weighting | 0.61 |
| Equity Weighting | 99.39 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 0.91 | 13.47 | 19.89 | 135.08 | 23.03 | 133.70 | 776.30 | 4,507.33 | 26,170.21 | 151,947.97 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -54.83 | -22.30 | -109.22 | -5.49 | -60.09 | -1,871.36 | -10,865.38 | -63,085.97 | -366,286.19 | -2,126,710.05 |
| Capital Expenditure | -0.06 | -0.07 | -0.02 | -0.35 | -0.04 | -1.99 | -11.53 | -66.95 | -388.72 | -2,256.99 |
| Free Cash Flow | -54.89 | -22.37 | -109.24 | -5.84 | -60.13 | -1,873.35 | -10,876.91 | -63,152.92 | -366,674.92 | -2,128,967.04 |
| WACC | ||||||||||
| PV LFCF | - | - | - | - | - | |||||
| SUM PV LFCF | - |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | - |
| Free cash flow (t + 1) | -2,171,546.38 |
| Terminal Value | - |
| Present Value of Terminal Value | - |
Intrinsic Value
| Enterprise Value | - |
|---|---|
| Net Debt | -9.78 |
| Equity Value | - |
| Shares Outstanding | 50.72 |
| Equity Value Per Share | - |